| |
| |
|
| Insider
Information: |
Harper Sean E |
| Relationship: |
10% Owner |
| City: |
Thousand Oaks |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
9,846,811 |
|
|
Indirect Shares
|
735,984 |
|
|
| Direct
Value |
$57,490,483 |
|
|
|
Indirect Value
|
$9,221,880 |
|
|
| Total
Shares |
10,582,795 |
|
|
| Total
Value |
$66,712,363 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -71.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
EVP, Research & Develo... |
2018-07-16 |
56,082 |
|
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
10% Owner |
2023-05-09 |
9,790,729 |
2023-05-09 |
0 |
Premium* |
|
|
Kyverna Therapeutics |
KYTX |
10% Owner |
2024-02-12 |
0 |
2024-02-12 |
735,984 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-01-31 |
4 |
D |
$191.27 |
$115,910 |
D/D |
(606) |
53,614 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-02-14 |
4 |
AS |
$174.18 |
$265,625 |
D/D |
(1,525) |
52,089 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,118 |
67,207 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-03-16 |
4 |
AS |
$189.75 |
$289,369 |
D/D |
(1,525) |
65,682 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-03-23 |
4 |
D |
$176.08 |
$1,329,228 |
D/D |
(7,549) |
58,313 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-04-12 |
4 |
AS |
$172.68 |
$263,337 |
D/D |
(1,525) |
56,788 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,508 |
61,296 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-05-03 |
4 |
D |
$169.43 |
$124,700 |
D/D |
(736) |
60,560 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-05-14 |
4 |
AS |
$174.10 |
$265,503 |
D/D |
(1,525) |
59,035 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-06-12 |
4 |
AS |
$184.27 |
$281,012 |
D/D |
(1,525) |
57,510 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2018-07-16 |
4 |
AS |
$195.71 |
$298,458 |
D/D |
(1,525) |
56,082 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
10% Owner |
– – • |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,540,729 |
8,540,729 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
10% Owner |
– – • |
2023-05-09 |
4 |
B |
$18.00 |
$22,500,000 |
D/D |
1,250,000 |
9,790,729 |
2.45 |
% |
|
| KYTX |
Kyverna Therapeutics |
10% Owner |
– – • |
2024-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
4,523,924 |
735,984 |
0 |
- |
|
64 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
